Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells
作者： Nabanita Mukherjee , Josianna V. Schwan , Mayumi Fujita , David A. Norris , Yiqun G. Shellman
DOI: 10.1038/JID.2015.145
关键词: Treatment regimen 、 Cancer stem cell 、 Oncology 、 Bcl-2 family 、 Internal medicine 、 Tumor heterogeneity 、 Melanoma 、 Immunology 、 Survival analysis 、 Cancer 、 Tumor initiating cell 、 Medicine
摘要: For the first time new treatments in melanoma have produced significant responses advanced diseases, but 30–90% of patients do not respond or eventually relapse after initial response to current treatments. The resistance these melanomas is likely due tumor heterogeneity, which may be explained by models such as stochastic, hierarchical, and phenotype-switching models. This review will discuss recent advancements targeting BCL-2 family members for cancer treatments, how this approach can applied an alternative option combat melanoma, overcome treatment regimens.
jidonline.org
core.ac.uk
elsevier.com
nature.com参考文章(102)
Matthew W. VanBrocklin, Kathryn M. Eisenmann, Susan M. Kitchen, Han Mo Koo, Nancy A. Staffend, Mitogen-Activated Protein Kinase Pathway-Dependent Tumor-Specific Survival Signaling in Melanoma Cells through Inactivation of the Proapoptotic Protein Bad Cancer Research. ,vol. 63, pp. 8330- 8337 ,(2003)
Keith S. Hoek, Colin R. Goding, Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell & Melanoma Research. ,vol. 23, pp. 746- 759 ,(2010) , 10.1111/J.1755-148X.2010.00757.X
Yuchun Luo, Katiuscia Dallaglio, Ying Chen, William A. Robinson, Steven E. Robinson, Martin D. McCarter, Jianbin Wang, Rene Gonzalez, David C. Thompson, David A. Norris, Dennis R. Roop, Vasilis Vasiliou, Mayumi Fujita, ALDH1A Isozymes are Markers of Human Melanoma Stem Cells and Potential Therapeutic Targets Stem Cells. ,vol. 30, pp. 2100- 2113 ,(2012) , 10.1002/STEM.1193
S C H Karlsson, A C Lindqvist, M Fransson, G Paul-Wetterberg, B Nilsson, M Essand, K Nilsson, P Frisk, H Jernberg-Wiklund, S I A Loskog, Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy Cancer Gene Therapy. ,vol. 20, pp. 386- 393 ,(2013) , 10.1038/CGT.2013.35
Farid Menaa, Latest approved therapies for metastatic melanoma: what comes next? Journal of skin cancer. ,vol. 2013, pp. 735282- 735282 ,(2013) , 10.1155/2013/735282
P. Nowell, The clonal evolution of tumor cell populations Science. ,vol. 194, pp. 23- 28 ,(1976) , 10.1126/SCIENCE.959840
Y Cheli, S Giuliano, N Fenouille, M Allegra, V Hofman, P Hofman, P Bahadoran, J-P Lacour, S Tartare-Deckert, C Bertolotto, R Ballotti, Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells Oncogene. ,vol. 31, pp. 2461- 2470 ,(2012) , 10.1038/ONC.2011.425
J. Tracy Watson, Teresa Foo, Jin Wu, Berton R. Moed, Margaret Thorpe, Lew Schon, Zijun Zhang, CD271 as a marker for mesenchymal stem cells in bone marrow versus umbilical cord blood. Cells Tissues Organs. ,vol. 197, pp. 496- 504 ,(2013) , 10.1159/000348794
Sevim Dalva-Aydemir, Richa Bajpai, Maylyn Martinez, Kehinde U.A. Adekola, Irawati Kandela, Changyong Wei, Seema Singhal, Jennifer E. Koblinski, Noopur S. Raje, Steven T. Rosen, Mala Shanmugam, Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin Clinical Cancer Research. ,vol. 21, pp. 1161- 1171 ,(2015) , 10.1158/1078-0432.CCR-14-1088
Mariusz L. Hartman, Malgorzata Czyz, Pro-survival role of MITF in melanoma. Journal of Investigative Dermatology. ,vol. 135, pp. 352- 358 ,(2015) , 10.1038/JID.2014.319